HBP.TOHelix BioPharma Corp.
This is the year Helix BioPharma Corp. (HBP.TO) has to prove it’s more than a biotech vaporware story.63 and a bull target of $2.00, while the bear fallback sits at $1.00. The market is leaning 63% toward the bull path, which is a strong signal, but it’s not a guarantee. The company has a 1σ expected move of 19.0%, which is a healthy amount of volatility for a small-cap biotech. If it clears this hurdle, the path is clear: L-DOS47 Phase 2 Clinical Update on 2026-12-15, then Q1 FY27 Earnings Release on 2027-01-26, and finally the Regulatory End-of-Phase Feed on 2027-04-14. Each of these events is a test, and the bull targets keep climbing, from $2.00 to $3.07, then $4.14, and finally $7.62. The bear paths, while lower, are still a meaningful range — $1.00, $1.84, $3.77, and $4.57. The market is betting on the bull, but the bear is always there, waiting. This is the year HBP.TO either becomes a real player or gets left behind.
The schedule
- Wed28Oct
Quarterly earnings release with guidance for FY26
- Tue15Dec
Update on Phase 2 clinical trial results for L-DOS47
- Tue26Jan
Earnings release for Q1 FY27 with guidance
- Wed14Apr
Regulatory update on end-of-phase feed for key drug
Past
- Tue8Sep
Actual outcome: Bear
The anticipated need for a secondary equity offering or private placement to secure operational runway weighed heavily on shares. Investors reacted negatively to the impending dilution risk, driving the stock down 12.2% as concerns over the company's capital structure and expanded share count took precedence.
High probability of a secondary equity offering or private placement to secure operational runway.
